ArticleEye (London, England)2025
Gonioscopy-assisted transluminal trabeculotomy outcomes in patients with highly advanced glaucoma.
Article in Eye (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesNo data regarding the outcomes of GATT in patients with highly advanced glaucoma are available. The aim of this study is to fill in this gap. SUBJECTS/
methodsThis is a multicentre, retrospective, and case-control study including highly advanced glaucoma patients (HVF Mean Deviation, MD < -20 dB, study group-SG) and controls (CG: MD > -20 dB). Sixty eyes (31 GATT stand-alone and 29 Phaco-GATT eyes) were included in each group. The SG and CG were compared until 12 months of follow-up, and survival analyses were performed.
resultsThe preoperative MD was -25.95 ± 3.64 dB in the SG and -7.96 ± 5.25 dB in the CG (p < 0.001). Preoperative IOP was 21.5 ± 8.2 mmHg in the SG on 3.4 ± 1.4 medications, and 20.8 ± 7.3 mmHg in the CG (p = 0.6) on 3.0 ± 0.9 medications (p = 0.1). At the 12-month visit, IOP was reduced by 39.1 ± 26.6% in the SG and 36.0 ± 18.7% in the CG (p = 0.4), and the number of preoperative medications was reduced by 62.2 ± 33.2% in the SG and 65.5 ± 37.4% in the CG (p = 0.6), with 93.3% of the eyes in the SG and 90.0% of the eyes in the CG having an IOP ≤ 14 mmHg, with or without medication (p = 0.5). No serious adverse events were observed in any of the groups.
conclusionGATT is a safe and effective surgical option for patients with highly advanced glaucoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.